Results 11 to 20 of about 8,428 (249)

Mesalamine-associated thrombocytopenia

open access: yesAmerican Journal of Gastroenterology, 1999
We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine.
Farrell, R. J.   +3 more
core   +4 more sources

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine [PDF]

open access: gold, 2013
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop.
Moss, Alan, Nanda, Kavinderjit
core   +3 more sources

Mesalamine in Ulcerative Colitis

open access: yesDICP, 1991
Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is
Jill Mancini Fitzgerald, T. Donald Marsh
core   +3 more sources

Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD

open access: yesAmerican Journal of Gastroenterology, 2014
OBJECTIVES: Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for ...
Moss, Alan   +7 more
core   +5 more sources

A novel pH–enzyme-dependent mesalamine colon-specific delivery system

open access: yesDrug Design, Development and Therapy, 2016
Lei Jin, Yi-cun Ding, Yu Zhang, Xiao-qing Xu, Qin Cao Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China Abstract: The aim of the present study was to ...
Jin L, Ding Y, Zhang Y, Xu X, Cao Q
doaj   +1 more source

Effectiveness of mesalamine and propolis in experimental colitis

open access: yesAdvances in Therapy, 2007
PubMedID: 18029336This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid.
Ahmet Aslan   +2 more
exaly   +2 more sources

Recurrent pleuropericarditis associated with mesalazine therapy masked by steroid use [PDF]

open access: yesEuropean Journal of Case Reports in Internal Medicine
Introduction: Mesalazine is a cornerstone therapy for ulcerative colitis (UC). Although generally safe, it can cause rare but life-threatening cardiopulmonary complications such as pleuropericarditis.
Hakan Demiröz   +6 more
doaj   +2 more sources

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

open access: yesDrug Design, Development and Therapy, 2011
Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first ...
Lilliana Oliveira, Russell D Cohen
doaj   +2 more sources

Proteomic profile of human colon organoids: effects of a multi-mineral intervention alone and in the presence of pro-inflammatory and anti-inflammatory treatments [PDF]

open access: yesFrontiers in Gastroenterology
IntroductionAquamin, a multi-mineral product derived from fossilized red marine algae, has been shown to improve colon barrier structure and function.
Muhammad Nadeem Aslam   +5 more
doaj   +2 more sources

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

open access: yesClinical and Experimental Gastroenterology, 2009
Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj   +1 more source

Home - About - Disclaimer - Privacy